Albert Labs leverages Real-World Evidence (RWE) studies across Europe to accelerate access to its proprietary psilocybin-based therapy for patients with urgent, unmet needs. MARCH 5th , 2021-VANCOUVER, BRITISH COLUMBIA, ME Resource Corp. (“MEC” or the “Company”) (CNSX: MEC | OTC: MEEXF) is pleased to announce the signing of a definitive agreement with Albert Labs Inc (“Albert Labs”) to complete a…


Previous articleNoetic Launches Second Fund to Invest in Emergent Psychedelic Medicine Sector
Next articlePTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians